Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Yesterday
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

Cancer patients at higher risk for CVD comorbidities prior to VEGF inhibitor use

Stephen Padilla
27 Feb 2020

Cancer patients who are eligible for the application of vascular endothelial growth factor (VEGF) antagonists have an increased risk for cardiovascular disease (CVD)-related comorbidities, with hypertension being the most prevalent condition, according to a study.

“Among [cancer patients with hypertension], those with grade III and very high cardiovascular risk level constitute the largest proportion,” the researchers said. “Also, hypertension patients had a significant burden of CVD comorbidity among the candidates for VEGF antagonist use.”

The top CVD comorbidities among cancer patients were hypertension, coronary heart disease, atrial fibrillation and heart failure. Of these, hypertension was the most prevalent (26.0 percent). [J Hypertens 2020;38:426-433]

Hypertension prevalence in patients with renal cell carcinoma (RCC; 33.5 percent) and colorectal cancer (CRC; 29.4 percent) was significantly higher than in those with hepatocellular carcinoma (HCC; 25.1 percent), lung cancer (24.5 percent) and thyroid cancer (23.1 percent).

Most cancer patients with hypertension had grade III (75.7 percent) and very high cardiovascular risk level (85.4 percent). Of the 5,847 hypertensive patients, 26 percent were not taking antihypertensive medication and 34.2 percent did not achieve their target blood pressure (BP).

The prevalence of hypertension among cancer patients in this study was comparable to that in the general population according to the latest China Hypertension Survey. [Circulation 2018;137:2344-2356]

In a previous study, Faruque and colleagues reported the association of increased BP with a higher burden of cardiovascular events, arterial thromboembolism and proteinuria. [PloS One 2014;9:e101145]

Hypertension may also reduce the therapeutic benefits of VEGF inhibitors, according to the researchers. Specifically, a study by Schmidinger revealed that 25–66 percent of cancer patients die of fatal events due to VEGF signaling pathway-related cardiotoxicity, which can develop to hypertension, arterial thromboembolism and myocardial infarction, among others. [EJC Suppl 2013;11:172-191]

Increasing evidence also showed that hypertension could influence the development of RCC. Studies have suggested that chronic renal hypoxia during hypertension could lead to upregulation of hypoxia-inducible factors, “which in turn plays a significant role in oncogenesis.” [J Am Soc Nephrol 2003;14:2703-2711; Am J Epidemiol 2008;167:438-446]

“A shred of evidence established that oxidative stress and lipid peroxidation are associated with hypertension, which are also known to play a critical role in the pathogenesis of RCC,” the researchers said. “However, the biological mechanism is still controversial and remained unclear.” [Am J Epidemiol 2008;167:438-446; N Engl J Med 1996;334:13-18; Nat Rev Cancer 2004;4:579-591]

The present study included 22,500 newly diagnosed cancer patients registered from 1 January 2011 to 31 December 2017. Those with CRC, RCC, thyroid cancer, HCC and lung cancer were enrolled.

Certain limitations were present, including the lack of detailed information on tumour size and stages formation, the possible underestimation of comorbidities prevalence, and the data sourced from a single centre with a relatively small sample size, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Yesterday
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.